Loading…
Loading…
See exactly how XPAY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for XPAY and 80,000+ other tickers.
The Roundhill S&P 500 Target 20 Managed Distribution ETF (XPAY) is an actively managed exchange-traded fund. It is structured to provide investors with monthly return of capital distributions, targeting an annualized rate of twenty percent, while simultaneously offering exposure to the S&P 500 index.
Roundhill S&P 500 Target 20 Managed Distribution ETF offers S&P 500 exposure via long call options with a 20% managed annual distribution. XPAY's simple structure and high payout suit income-focused investors, but long-term reinvestors are likely better off with SPDR S&P 500 ETF Trust. XPAY distributions are primarily return of capital, providing tax deferral benefits similar to or better than SPY's tax efficiency.
The Roundhill S&P 500 Target 20 Managed Distribution ETF (XPAY) targets a 20% annual distribution via a synthetic, option-based structure. XPAY's high yield is funded by selling deep in-the-money SPY FLEX options, causing NAV erosion unless the S&P 500 returns at least 20% annually. It becomes in my opinion a tax-efficient solution to distribute capital in strong markets.
Roundhill S&P 500 Target 20 Managed Distribution ETF is rated Hold due to structural NAV erosion and unsustainably high-yield targets. XPAY's ~20% yield is only sustainable if SPY grows at a 20% CAGR, making long-term income growth unlikely and exposing payouts to significant downside in flat or weak markets. The ETF's synthetic SPY exposure via deep in-the-money FLEX options offers minimal yield beyond core SPY, with structural drag compounding over time and total returns lagging SPY by about 1.5 percentage points annually.
Guru Stock PicksCatherine Wood has made the following transactions:Reduce in NXDR by 2.41%Sold out in KMDAAdd in FVRR by 24%New position in IWBPRIMECAP Manageme
Stock News FDA refuses to file Moderna's flu shot: Moderna (MRNA) said the FDA issued a refusal-to-file letter for its mRNA flu vaccine application, citing tria